FGFR1 and urinary bladder cancer: Two non‐selective FGFR1–3 inhibitors, erdafitinib (JNJ‐42756493) and pemigatinib (INCB054828) have been approved and are being marketed to treat bladder cancer and cholangiocarcinoma in patients with FGFR2 or FGFR3 rearrangements.10, 11